Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 2
2004 4
2005 2
2006 1
2008 3
2009 6
2010 4
2011 5
2012 7
2013 4
2014 3
2015 7
2016 7
2017 10
2018 14
2019 27
2020 20
2021 9
2022 12
2023 14
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

154 results

Results by year

Filters applied: . Clear all
Page 1
Epidemiology of Diabetic Kidney Disease among US Veterans.
Kim K, Crook J, Lu CC, Nyman H, Abdelaziz A, LaFleur J. Kim K, et al. Diabetes Metab Syndr Obes. 2024 Apr 8;17:1585-1596. doi: 10.2147/DMSO.S450370. eCollection 2024. Diabetes Metab Syndr Obes. 2024. PMID: 38616990 Free PMC article.
Emerging Insights into the Use of Advanced Nanomaterials for the Electrochemiluminescence Biosensor of Pesticide Residues in Plant-Derived Foodstuff.
Shelash Al-Hawary SI, Malviya J, Althomali RH, Almalki SG, Kim K, Romero-Parra RM, Fahad Ahmad A, Sanaan Jabbar H, Vaseem Akram S, Hussien Radie A. Shelash Al-Hawary SI, et al. Among authors: kim k. Crit Rev Anal Chem. 2023 Sep 20:1-18. doi: 10.1080/10408347.2023.2258971. Online ahead of print. Crit Rev Anal Chem. 2023. PMID: 37728973 Review.
Correction to: RE‑MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola‑BR), CAR‑T therapies, and lenalidomide/rituximab (R2) based on real‑world data in patients with relapsed/refractory diffuse large B‑cell lymphoma.
Nowakowski GS, Yoon DH, Mondello P, Joffe E, Peters A, Fleury I, Greil R, Ku M, Marks R, Kim K, Zinzani PL, Trotman J, Sabatelli L, Waltl EE, Winderlich M, Sporchia A, Kurukulasuriya NC, Cordoba R, Hess G, Salles G. Nowakowski GS, et al. Among authors: kim k. Ann Hematol. 2023 Sep;102(9):2643-2644. doi: 10.1007/s00277-023-05321-3. Ann Hematol. 2023. PMID: 37432417 Free PMC article. No abstract available.
RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma.
Nowakowski GS, Yoon DH, Mondello P, Joffe E, Peters A, Fleury I, Greil R, Ku M, Marks R, Kim K, Zinzani PL, Trotman J, Sabatelli L, Waltl EE, Winderlich M, Sporchia A, Kurukulasuriya NC, Cordoba R, Hess G, Salles G. Nowakowski GS, et al. Among authors: kim k. Ann Hematol. 2023 Jul;102(7):1773-1787. doi: 10.1007/s00277-023-05196-4. Epub 2023 May 12. Ann Hematol. 2023. PMID: 37171597 Free PMC article.
154 results